Clinical trials: Metastatic Biliary Tract Carcinoma
Cancer
Ondansetron With/Out Dexamethasone to Prevent Vomiting in Patients Receiving Radiation to the Upper Abdomen
RATIONALE: Antiemetic drugs may help to reduce or prevent vomiting in patients treated with radiation therapy. It is not yet known if ondansetron is more effective with or without dexamethasone in preventing vomiting caused by…
- Trial name
- NCT00016380
- Testing
- dexamethasone, ondansetron, quality-of-life assessment
- Where
- 14 sites in Canada
- Volunteers
- 211 people
- Sponsor
- NCIC Clinical Trials Group
Cholangiocarcinoma, Liver and Intrahepatic Bile Duct Carcinoma
Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery
This phase II trial studies how well ramucirumab works in treating patients with previously treated biliary cancers that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced)…
- Conditions
- Cholangiocarcinoma, Liver and Intrahepatic Bile Duct Carcinoma, Stage III Gallbladder Cancer AJCC v7, Stage III Intrahepatic Cholangiocarcinoma AJCC v7
- Trial name
- NCT02520141
- Testing
- Laboratory Biomarker Analysis, Ramucirumab
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- M.D. Anderson Cancer Center
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer
RATIONALE: Drugs used in chemotherapy, such as capecitabine, epirubicin, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Liver Cancer
- Trial name
- NCT00486356
- Testing
- capecitabine, carboplatin, epirubicin hydrochloride
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- University of Nebraska
Advanced or Metastatic Biliary Tract Cancer, Advanced or Metastatic Solid Tumors
A Study of Varlitinib in Japanese Subjects With Advanced or Metastatic Solid Tumours
The purpose of this study is to explore safety and efficacy of varlitinib administered as monotherapy in Japanese subjects with advanced or metastatic solid tumors, and administered as combination with capecitabine in Japanese…
- Trial name
- NCT03082053
- Testing
- varlitinib, capecitabine
- Where
- Japan
- Volunteers
- 24 people
- Sponsor
- ASLAN Pharmaceuticals
Advanced or Metastatic Biliary Tract Cancer
Study of Varlitinib Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer
The purpose of the study is to assess the efficacy of varlitinib in combination with capecitabine as measured by objective response rate (ORR) assessed by independent central review (ICR), based on RECIST v1.1 criteria.
- Trial name
- NCT03129074
- Testing
- Varlitinib, Capecitabine
- Sponsor
- ASLAN Pharmaceuticals
Metastatic Biliary Tract Carcinoma, Metastatic Colorectal Carcinoma
Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer
This phase I/II trial studies the side effects and best dose of liposomal irinotecan and rucaparib when given together with fluorouracil and leucovorin calcium and to see how well they work in treating patients with pancreatic…
- Conditions
- Metastatic Biliary Tract Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Digestive System Neoplasm
- Trial name
- NCT03337087
- Testing
- Fluorouracil, Irinotecan Sucrosofate, Laboratory Biomarker Analysis
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Academic and Community Cancer Research United
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
This phase I trial is studying the side effects and best dose of erlotinib hydrochloride when given together with cetuximab and to see how well they work in treating patients with advanced gastrointestinal cancer, head and neck…
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
- Trial name
- NCT00397384
- Testing
- cetuximab, erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- National Cancer Institute (NCI)
Biliary Tract Cancer
Docetaxel and Oxaliplatin Combination With Locally Advanced or Metastatic Biliary Tract Cancer
1. Goals The primary goal of this phase II trial is to: evaluate the response rate of combination chemotherapy with docetaxel and oxaliplatin in patients with locally advanced or metastatic BTC as first-line therapy Secondary…
- Trial name
- NCT01234051
- Testing
- Docetaxel, Oxaliplatin
- Where
- South Korea
- Volunteers
- 53 people
- Sponsor
- Korean South West Oncology Group
Metastatic Disease
BIBW 2992 as add-on to Gem/Cis in Advanced Biliary Tract Cancer
An open-label, uncontrolled, multicenter phase I/Ib trial to investigate safety and efficacy of BIBW 2992 added to the standard therapy of Gemcitabine/Cisplatin in chemo-naïve patients with advanced and/or metastatic…
- Trial name
- NCT01679405
- Testing
- BIBW 2992
- Where
- Germany
- Volunteers
- 9 people
- Sponsor
- Johannes Gutenberg University Mainz
Metastatic Biliary Tract Cancer, HER2 Positive
Inetetamab Plus Chemotherapy ± PD-1/PD-L1 in HER2+ Advanced Biliary Cancer
To evaluate the efficacy and safety of inetetamab in combination with chemotherapy ± immunotherapy as a first-line treatment for HER2-positive advanced biliary tract cancer, providing theoretical evidence and practical guidance…
- Trial name
- NCT06818773
- Testing
- Inetetamab + Gemcitabine + Cisplatin ± PD-1/PD-L1 inhibitor
- Volunteers
- 35 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Cancer
High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill…
- Trial name
- NCT00002854
- Testing
- filgrastim, carboplatin, cisplatin
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- City of Hope Medical Center
Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
This study will assess the safety and efficacy of VS-7375 alone and in combination in patients with advanced solid tumors harboring a KRAS G12D-mutation.
- Conditions
- Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Adult
- Trial name
- NCT07020221
- Testing
- VS-7375, Cetuximab, Carboplatin + Pemetrexed + Pembrolizumab
- Where
- 20 sites in United States, Australia and 2 more
- Volunteers
- 616 people
- Sponsor
- Verastem, Inc.
Biliary Tract Neoplasms
TST001 in Patients With CLDN18.2 Positive Previously Treated Advanced Biliary Tract Cancer
TST001 is a recombinant humanized anti-Claudin 18.2 (CLDN18.2) IgG1 monoclonal antibody. This is an open-label, single-arm phase II study to evaluate the efficacy and safety of TST001 for patients with CLDN18.2 positive…
- Trial name
- NCT05190575
- Testing
- TST001
- Where
- China
- Volunteers
- 8 people
- Sponsor
- Shanghai Zhongshan Hospital
Cancer
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
Phase I trial to study the effectiveness of trastuzumab plus R115777 in treating patients who have advanced or metastatic cancer.
- Trial name
- NCT00005842
- Testing
- trastuzumab, tipifarnib
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Biliary Tract Carcinoma
Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer
This study will investigate the safety and effectiveness of a new combination treatment for patients with advanced bile duct cancer.
- Trial name
- NCT07392541
- Testing
- Adebrelimab, Gemcitabine + Cisplatin, Simvastatin 20mg
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Tongji Hospital
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Dolastatin 10 in Treating Patients With Metastatic Or Recurrent Liver, Bile Duct, or Gallbladder Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of dolastatin 10 in treating patients with metastatic or…
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer
- Trial name
- NCT00003557
- Testing
- dolastatin 10
- Where
- 11 sites in United States
- Volunteers
- 16 people
- Sponsor
- University of Chicago
Unresectable, Locally Advanced
Cetuximab + Gemox in Biliary Tract Cancer
The aim of this prospective single-centre phase II study is to investigate the therapeutic efficacy and safety of cetuximab in combination with Gemcitabine and Oxaliplatin (GEMOX) in the palliative first line treatment of biliary…
- Conditions
- Unresectable, Locally Advanced, Metastatic
- Trial name
- NCT01216345
- Testing
- Cetuximab + Gemcitabine + Oxaliplatin
- Where
- Austria
- Volunteers
- 30 people
- Sponsor
- Association of Research on the Biology of Liver Tumors
Hepatocellular Cancer, Hepatocellular Carcinoma
Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma
Background: Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world. Most people with advanced HCC survive an average of 6 to 9 months.
- Conditions
- Hepatocellular Cancer, Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
- Trial name
- NCT03937830
- Testing
- durvalumab, Doxorubicin-Eluting Beads, TACE
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Biliary Tract Carcinoma, Metastatic Colon Carcinoma
BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion
This phase Ib/II trial tests the safety and side effects of BMS-986504 in combination with pemetrexed and how well the combination works in treating patients with solid tumors with MTAP deletion and that has spread from where it…
- Conditions
- Metastatic Biliary Tract Carcinoma, Metastatic Colon Carcinoma, Metastatic Esophageal Carcinoma, Metastatic Malignant Digestive System Neoplasm
- Trial name
- NCT07594626
- Testing
- Biospecimen Collection, Computed Tomography, Pemetrexed
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Northwestern University
Advanced Solid Tumors, Genital Neoplasm, Female
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent and in combination with chemotherapy administered intravenously in participants…
- Conditions
- Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm
- Trial name
- START-001 (NCT05592626)
- Testing
- STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere)
- Where
- 19 sites in United States, Canada and 2 more
- Volunteers
- 366 people
- Sponsor
- Marengo Therapeutics, Inc.